Guardant Health’s blood-based multi-cancer screening test receives FDA Breakthrough Designation

Guardant Health’s blood-based multi-cancer screening test receives FDA Breakthrough Designation

Guardant Health's Shield multi-cancer screening test detects multiple cancer types with a single blood draw, promising early diagnosis for various cancers.

Guardant Health's MCD test earns FDA breakthrough designation

Guardant Health's Shield multi-cancer detection (MCD) test has secured the US Food and Drug Administration’s (FDA) breakthrough device designation.The post Guardant Health’s MCD test earns FDA breakthrough designation appeared first on Medical Device Network.